Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2018 Jun 22;20(Suppl 2):i63. doi: 10.1093/neuonc/noy059.162

DIPG-69. CHARACTERISTICS OF PATIENTS ≥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY

Craig Erker 1, Adam Lane 1, Brooklyn Chaney 1, Nancy Yanez Escorza 1, Christine Fuller 1, Raya Saab 2, Mark Kieran 3, Roger Packer 4, Javad Nazarian 4, Jane Minturn 5, Andrew Dodgshun 6, Sarah Parkin 6, Nicholas Foreman 7, Emmett Broxson 8, Mercedes Garcia Lombardi 9, Stewart Goldman 10, Eric Sandler 11, Kathy Warren 12, Robert Greiner 13, Nickolas Gottardo 14, Hetal Dholaria 14, Chie-Schin Shih 15, Tim Hassall 16, Jordan R Hansford 17, Shiqi Stacie Wang 17, Yvan Samson 18, Sarah Leary 19, Jie Ma 20, Ute Bartels 21, Alberto Broniscer 22, Michelle Monje 23, Paul Fisher 23, David Ziegler 24, Lars Wagner 25, Carl Koschmann 26, Renee Doughman 1, Rachid Drissi 1, Blaise Jones 1, James Leach 1, Peter White 1, Phillip Dexheimer 1, Jacob Hendershot 1, Cynthia Hawkins 21, Pratiti Bandopadhayay 3, Maryam Fouladi 1
PMCID: PMC6012641

Abstract

INTRODUCTION

Patients ≥10 years of age with a DIPG are reported to have a higher rate of long-term survival (≥24 months). The purpose of this study was to compare clinical, radiological, pathological and molecular characteristics between patients ≥10 years old with DIPG who were long-term survivors (LTS) vs short-term survivors (STS) and assess biological differences in this age group compared to patients <10 years old.

METHODS

Data were abstracted from the International DIPG Registry (IDIPGR) for patients ≥10 years old at diagnosis. Imaging was reviewed and those with typical radiographic findings of DIPG were included. The primary outcome was overall survival (OS) categorized as LTS (≥24 months) or STS (<24 months).

RESULTS

Among 782 patients with abstracted data in the IDIPGR, 170 were ≥10 years of age (22%). The median age and OS [range] were 12.5 [10.0–26.8] years and 15 [2–82] months, respectively; 12.8% were LTS. Biopsy or autopsy were performed in 38% of patients; 83% of patients were H3 K27M-mutant. LTS were found to have longer symptom duration before presentation, lower WHO grade and larger tumor size compared to STS. WGS and RNA sequencing are being conducted.

CONCLUSION

The rate of LTS in patients ≥10 years of age is approximately 13%. Preliminarily, clinical and imaging parameters associated with LTS in this population are similar to general DIPG cohorts. Biological data will be presented for the approximately 38% of patients with available tissue to delineate potential predictors of outcome.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES